Japan Tissue Engineering Co

Japan Tissue Engineering Co Net Debt / EBITDA

The Net Debt to EBITDA of Japan Tissue Engineering Co (7774.T) as of Oct 21, 2026 is -25.13. In the previous year, Net Debt to EBITDA was 5.85 — a change of -529.60% (lower).

Net Debt / EBITDA

-25.13

YoY

-529.60%

Last updated:

Net Debt to EBITDA of Japan Tissue Engineering Co is 2024 -25.13 . Net Debt to EBITDA of Japan Tissue Engineering Co was 2023 5.85 . It decreases by -529.60% lower compared to the previous year.

The Japan Tissue Engineering Co Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2017
-12.31 JPY
Jan 1, 2018
-25.44 JPY
Jan 1, 2019
18.13 JPY
Jan 1, 2020
26.25 JPY
Jan 1, 2021
11.80 JPY
Jan 1, 2022
10.27 JPY
Jan 1, 2023
5.85 JPY
Jan 1, 2024
-25.13 JPY
The Japan Tissue Engineering Co Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
-25.13-529.60%
5.85-43.03%
10.27-12.98%
11.80-55.06%
26.25+44.84%
18.13-171.24%
-25.44+106.71%
-12.31-391.17%
4.23-37.69%
6.78+791.20%
0.76-68.66%
2.43-45.25%
4.44-30.92%
6.42+302.88%
1.59-52.18%
3.33-35.16%
5.14+52.90%
3.36—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Japan Tissue Engineering Co Stock analysis

What does Japan Tissue Engineering Co do? Japan Tissue Engineering Co., Ltd. generates revenue through three business segments. The Regenerative Medicine Product segment sells autologous cultured epidermis JACE and autologous cultured cartilage JACK to medical institutions. The Regenerative Medicine Outsourcing segment offers CDMO, CRO, consulting, and contract manufacturing services for cell processed products. The Research and Development Support segment sells human cultured tissues developed using the company's advanced culture technology. Medical institutions purchase regenerative medicine products, while pharmaceutical and biotech companies utilize outsourcing services for cell-based therapies. The company's products are sold to healthcare providers and research-focused clients across Japan and potentially internationally. The Regenerative Medicine Product segment focuses on selling JACE and JACK, which are used in medical treatments requiring tissue regeneration. These products are specifically designed for autologous use, meaning they are derived from the patient's own cells. The Outsourcing segment provides specialized services to support the development and manufacturing of cell-based therapies, targeting pharmaceutical and biotech firms. The Research and Development Support segment supplies tissues for research applications, leveraging the company's internal technology to meet client needs in scientific development. JACE and JACK are key products in the Regenerative Medicine Product segment, directly sold to medical institutions for clinical use. The Outsourcing segment serves as a service provider for cell therapy development, offering CDMO and CRO capabilities. The Research and Development Support segment's human cultured tissues are marketed to research organizations seeking advanced cell culture solutions. All segments contribute to the company's revenue by addressing specific needs in regenerative medicine and cell therapy development. Japan Tissue Engineering Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Japan Tissue Engineering Co stock

Net Debt to EBITDA of Japan Tissue Engineering Co is -25.13 in 2024.

Net Debt to EBITDA of Japan Tissue Engineering Co changed from 5.85 to -25.13, representing a -529.60% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA Japan Tissue Engineering Co since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's Japan Tissue Engineering Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — Japan Tissue Engineering Co

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — Japan Tissue Engineering Co